Supernus Pharmaceuticals is up 1.8% during the same time and is heading into earnings with an average analyst price target of $38.80 (compared to the current share price of $32.84).

Supernus' reliance on Qelbree is increasing, with significant revenue growth in 2024, but generic competition for other drugs poses challenges. Management's 2025 guidance led to a stock sell-off ...

Supernus Pharmaceuticals' stock has risen 15% since my last "strong buy" rating, despite recent analyst downgrades due to Qelbree's slowing growth. Supernus' diverse neuroscience portfolio ...

Mumbai: Lupin Limited has announced that it has received tentative approval from the United States Food and Drug ...

Supernus Pharmaceuticals, Inc. Qelbree ® net product sales growth of 179% and 193% in the first three months and first six months of 2023, respectively, compared to the same periods in 2022 $31.0 ...

Supernus Pharmaceuticals, Inc. Fourth quarter 2023 net sales of Qelbree ® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to ...

Supernus Pharmaceuticals Inc., a Rockville pharmaceutical company, on Thursday announced pricing of its private offering of $350 million of 0.625 percent convertible bonds due 2023.

ROCKVILLE, Md., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of ...

Supernus Pharmaceuticals Inc., a Rockville-based pharmaceutical company focused on products for the treatment of central nervous system diseases, reported ...